Synthetic cannabinoids (SC) remain one of the largest groups of new psychoactive substances (NPS) on the European drug market. In December 2018, Cumyl-CH-MEGACLONE, a novel SC based on a γ-carboline-1-one core structure was firstly identified in Hungary, and later also other European countries. This work aims to reveal the pharmacological characteristics and phase-I metabolism of Cumyl-CH-MEGACLONE and compare the data to its analogs Cumyl-PEGACLONE and 5F-Cumyl-PEGACLONE.

中文翻译：

---

新型精神活性物质Cumyl-CH-MEGACLONE：人类I期代谢，基本药理学特征以及与其他具有γ-Carboline-1-one核心的合成大麻素受体激动剂的比较。

合成大麻素（SC）仍然是欧洲毒品市场上最大的新型精神活性物质（NPS）组之一。2018年12月，Cumyl-CH-MEGACLONE（一种基于γ-咔啉-1-一个核心结构的新型SC）在匈牙利以及其他欧洲国家首次被发现。这项工作旨在揭示Cumyl-CH-MEGACLONE的药理特性和I期代谢，并将数据与其类似物Cumyl-PEGACLONE和5F-Cumyl-PEGACLONE进行比较。